Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation-Reference-Cited by-同舟云学术

Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation

Published:2023-01 Issue: Volume:126 Page:39-47
ISSN:1201-9712
Container-title:International Journal of Infectious Diseases
language:en
Short-container-title:International Journal of Infectious Diseases

Author:

Tsai Mao-Song^ORCID,Sun Hsin-Yun,Chen Cheng-Pin^ORCID,Lee Chen-Hsiang,Lee Chun-Yuan,Liu Chun-Eng,Tang Hung-Jen,Hung Tung-Che^ORCID,Li Chia-Wen,Lee Yuan-Ti,Liou Bo-Huang,Yang Chia-Jui,Hung Chien-Ching

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference44 articles.

1. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial;Aboud;Lancet Infect Dis,2019

2. Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) from dolutegravir (DTG)+F/TAF or DTG+F/tenofovir disoproxil fumarate (TDF) in the presence of pre-existing NRTI resistance;Acosta;J Acquir Immune Defic Syndr,2020

3. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I;Andreatta;J Antimicrob Chemother,2019

4. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the second-LINE trial: an exploratory analysis;Boyd;Lancet HIV,2015

5. Meta-analysis of efficacy and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide among people living with HIV;Chen;Infect Dis Ther,2021

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in treatment-naïve and treatment-experienced people with HIV: Findings from the Asia cohort of the BICSTaR study;Journal of Microbiology, Immunology and Infection;2024-07

2. Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV using real-world data: a systematic review and meta-analysis;Journal of Antimicrobial Chemotherapy;2024-05-17

3. Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV;Journal of Clinical Medicine;2023-12-18

4. Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH);Infectious Disease Reports;2023-12-11

5. Clinical significance and management of low‐level HIV viremia in the era of integrase strand transfer inhibitors;HIV Medicine;2023-11-22